These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38961804)

  • 1. Estimating survival scenarios in advanced or metastatic gastric and oesophageal adenocarcinoma: a systematic review of randomized-controlled trials.
    Naher SK; Mercieca-Bebber R; Siu D; Stockler MR; Kiely BE; Grimison P
    Curr Med Res Opin; 2024 Aug; 40(8):1357-1367. PubMed ID: 38961804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy.
    Smith-Uffen M; Park J; Parsonson A; Kiely BE; Vasista A
    Oncologist; 2024 May; ():. PubMed ID: 38768122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials.
    Vasista A; Stockler MR; West T; Wilcken N; Kiely BE
    Breast; 2017 Feb; 31():99-104. PubMed ID: 27829202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.
    Kiely BE; Soon YY; Tattersall MH; Stockler MR
    J Clin Oncol; 2011 Feb; 29(4):456-63. PubMed ID: 21189397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: a systematic review of randomised trials.
    West TA; Kiely BE; Stockler MR
    Eur J Cancer; 2014 Jul; 50(11):1916-24. PubMed ID: 24825113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond the median: Estimating survival times for patients starting endocrine therapy for estrogen receptor-positive, metastatic breast cancer from recent randomized trials.
    Parsonson AO; Sarkar S; Brown L; Low GKK; Kiely BE; Vasista A
    Asia Pac J Clin Oncol; 2024 Jun; ():. PubMed ID: 38881159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trials.
    Kiely BE; Alam M; Blinman P; Tattersall MH; Stockler MR
    Lung Cancer; 2012 Sep; 77(3):537-44. PubMed ID: 22609149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.
    Davidson M; Cafferkey C; Goode EF; Kouvelakis K; Hughes D; Reguera P; Kalaitzaki E; Peckitt C; Rao S; Watkins D; Chau I; Cunningham D; Starling N
    Clin Colorectal Cancer; 2018 Sep; 17(3):223-230. PubMed ID: 29980492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in best-case, typical and worst-case survival scenarios of patients with non-metastatic esophagogastric cancer between 2006 and 2020: A population-based study.
    Kuijper SC; Pape M; Vissers PAJ; Jeene PM; Kouwenhoven EA; Haj Mohammad N; Ruurda JP; Sosef MN; Verhoeven RHA; van Laarhoven HWM
    Int J Cancer; 2023 Jul; 153(1):33-43. PubMed ID: 36855965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
    Chau I; Norman AR; Cunningham D; Oates J; Hawkins R; Iveson T; Nicolson M; Harper P; Seymour M; Hickish T
    Ann Oncol; 2009 May; 20(5):885-91. PubMed ID: 19164454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond Median Overall Survival: Estimating Trends for Multiple Survival Scenarios in Patients With Metastatic Esophagogastric Cancer.
    Pape M; Kuijper SC; Vissers PAJ; Beerepoot LV; Creemers GJ; van Laarhoven HWM; Verhoeven RHA
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1321-1329.e4. PubMed ID: 36509070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials.
    Thientosapol ES; Tran TT; Della-Fiorentina SA; Adams DH; Chantrill L; Stockler MR; Kiely BE
    Intern Med J; 2013 Aug; 43(8):883-8. PubMed ID: 23656187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer.
    Vasista A; Stockler M; Martin A; Pavlakis N; Sjoquist K; Goldstein D; Gill S; Jain V; Liu G; Kannourakis G; Kim YH; Nott L; Snow S; Burge M; Harris D; Jonker D; Chua YJ; Epstein R; Bonaventura A; Kiely B
    Oncologist; 2019 Nov; 24(11):e1102-e1107. PubMed ID: 30936377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature.
    Kamposioras K; Ntellas P; Nikolaou M; Germetaki T; Gazouli I; Dadouli K; Zarkavelis G; Amylidi AL; Tolia M; Mauri D
    JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34926989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A reliable risk score for stage IV esophagogastric cancer.
    Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
    Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma.
    Cronin-Fenton DP; Mooney MM; Clegg LX; Harlan LC
    World J Gastroenterol; 2008 May; 14(20):3165-73. PubMed ID: 18506920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
    Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
    Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
    Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A response to: Artificial immortalization, number of therapy lines, and survival of patients with advanced gastric and esophagogastric adenocarcinoma.
    Bišof V; Katić A; Soče M; Vidović M; Viculin J; Pleština S; Vrdoljak E
    Neoplasma; 2024 Aug; 71(4):415-416. PubMed ID: 39267537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data.
    Hamers PAH; Elferink MAG; Stellato RK; Punt CJA; May AM; Koopman M; Vink GR
    Int J Cancer; 2021 Jan; 148(2):296-306. PubMed ID: 32638384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.